SCHEMBL21904034

SCHEMBL21904034

Cn1nccc1C(=O)NCC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.65
KMT2A Q03164 1/20 0.65
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
NAMPT P43490 1/20 0.49
EGLN1 Q9GZT9 2/20 0.48
ITGAV P06756 1/20 0.47
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
PRMT5 O14744 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL30468551 0.98 L3MBTL1 (0.63) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL29048025 0.98 L3MBTL1 (0.63) L3MBTL1KMT2ARAB9ANPC1CYP1A2
Lithium Ion SCHEMBL21904259 0.84 KMT2A (0.61) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL21904387 0.84 KMT2A (0.61) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL1520499 0.84 L3MBTL1 (0.61) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL3410537 0.83 KMT2A (0.69) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL21904003 0.81 KMT2A (0.55) L3MBTL1KMT2ARAB9ANPC1CYP2D6
SCHEMBL31505932 0.80 KMT2A (0.65) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL12424226 0.80 KMT2A (0.65) L3MBTL1KMT2ARAB9ANPC1CYP1A2
SCHEMBL7899244 0.79 KMT2A (0.63) L3MBTL1KMT2ARAB9ANPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110769821-B Spiro indolines as IL-17 modulators UCB生物制药有限责任公司 2023-07-07 CN disclosed
EP-3638227-B1 SPIROCYCLIC INDOLINES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2022-08-10 EP disclosed
US-11052076-B2 Spirocyclic indolines as IL-17 modulators UCB Biopharma SRL (BE) 2021-07-06 US disclosed
US-20200138797-A1 Spirocyclic Indolines as IL-17 Modulators UCB Biopharma SRL (BE) 2020-05-07 US disclosed
CN-110769821-A Spirocyclic indolines as IL-17 modulators UCB生物制药私人有限公司 2020-02-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052076-B2 Spirocyclic indolines as IL-17 modulators IL17A, IL2, IL18 L3MBTL1 4331/4885KMT2A 2550/4885RAB9A 2204/4885
US-20200138797-A1 Spirocyclic Indolines as IL-17 Modulators IL17A, IL2, IL18 L3MBTL1 4331/4885KMT2A 2550/4885RAB9A 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.